Treatment satisfaction remained 85% at ten years after prostate LDR brachytherapy
At ten years after prostate LDR brachytherapy, 85% of respondents remained satisfied, while bowel quality of life remained independently associated with satisfaction.
Tag
ldr-brachytherapy
Iodine-125 brachytherapy achieved short-term control in previously irradiated cervical nodal metastases
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Higher-dose iodine-125 brachytherapy was associated with longer survival in recurrent glioblastoma
Iodine-125 doses of 140–160 grays were associated with longer median survival than 120–140 grays in recurrent glioblastoma.